Neurofit (Co-CEOs Bin Jun-gil and Kim Dong-hyun) , a company specializing in artificial intelligence (AI) for brain disease diagnosis and treatment, announced on the 14th that it will establish a local corporation in Delaware, USA, and begin full-scale conquest of the US market.
This incorporation is a strategic move to fully supply Neurofit's AI-based brain disease solutions to the United States. The new entity will be wholly owned by Neurofit, and the incorporation process is expected to be completed within this month.
According to market research firm Grand View Research, the U.S. Alzheimer's disease treatment market is projected to grow to $6.441 billion (approximately KRW 9.185 trillion) by 2030. Furthermore, the Alzheimer's Association projects that the number of Alzheimer's disease patients in the United States will reach approximately 7.2 million by 2025.
Accordingly, Neurofit plans to use the establishment of this local corporation as an opportunity to accelerate business development in the U.S. market, expand partnerships with local medical institutions and companies, and actively pursue securing new customers.
Neurofit began its foray into the Japanese market in August by signing a supply agreement with a Japanese medical institution for its brain imaging analysis solution, "NEUROPHET AQUA." The establishment of this US subsidiary marks the company's second global base, following Japan, and marks the beginning of a major acceleration in its overseas expansion.
“The U.S. is a key market with high demand for AI-based brain disease diagnosis and treatment technologies,” said Bin Jun-gil, co-CEO of Neurofit. “We will strengthen our customized strategy in the U.S., focusing on our local corporation, and strive to provide more effective solutions to global patients.”
- See more related articles
You must be logged in to post a comment.